1. Pink Sheet
  2. >>Archive

Pfizer Moves CNS And Cardio-Metabolic Research To Cambridge, Mass., Promotes Cross-Talk With Local Scientists

 
• By Michael Goodman

Pfizer has relocated its neuroscience and cardiovascular medicine research groups from Groton, Conn., to Cambridge, Mass. Currently in temporary labs, the research will move into permanent space in 2013. The goal is to foster cross-talk and collaboration with local scientists and with Pfizer’s CTI program in nearby Boston.

Pfizer Inc. is in the midst of moving its cardiovascular and neuroscience research units from Groton, Conn., to Cambridge, Mass., with a goal of completing the relocation fully next year. It’s a process that began in February 2011, when the pharma first announced plans to move the two divisions; in September 2011, it signed a lease with Massachusetts Institute of Technology, giving it 180,000 square feet of newly constructed lab and office space in Cambridge’s Kendall Square.

The new building, at 610 Main Street, is scheduled for completion in the fourth quarter of 2013. In the meantime, the groups will be housed in temporary spaces. The cardiovascular...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 
• By Neena Brizmohun

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Nielsen Hobbs

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Nielsen Hobbs

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 
• By Francesca Bruce

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

Darzalex Faspro Gains US FDA AdComm Support For Smoldering Myeloma Claim

 
• By Bridget Silverman

The use of J&J’s Darzalex Faspro in high-risk smoldering multiple myeloma could result in overtreatment, but the FDA committee voted in favor of the new claim for delay in development of multiple myeloma.

STARGLO Dulled: Genentech’s Columvi Data Not Generalizable To US Patients, FDA Panel Says

 
• By Sue Sutter

The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.